Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/24/2007 First Published: 6/8/2007


1.		Phase I/II Study of Hydroxychloroquine, Radiotherapy, and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NABTT-0603 0603, NCT00486603

Last Modified: 12/3/2008 First Published: 12/4/2007


2.		Phase I/II Study of Hydroxychloroquine and Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				UPCC-01407 UPCC 01407, UPCC-IRB-806149, NCT00568880

Last Modified: 11/6/2008 First Published: 7/24/2008


3.		Phase I/II Study of Hydroxychloroquine in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Recurrent Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				CINJ-030801 030801, NCT00728845

First Published: 9/23/2008


4.		Phase I/II Study of Ixabepilone and Hydroxychloroquine in Patients With Taxane- and Anthracycline-Resistant Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Approved-not yet active				18 and over				NCI				CINJ-040804 040804, CINJ-0220080205, NCT00765765


5.		Hydroxychloroquine and Gefitinib to Treat Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				21 and over				Other, Pharmaceutical / Industry				NS 01/03/08 NCT00809237

First Published: 7/30/2008


6.		Phase II Study of Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen (PSA) Progression After Local Therapy for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				CINJ-080803 080803, NCT00726596


7.		Hydroxychloroquine in Untreated B-CLL Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other				08-088 NCT00771056

Last Modified: 12/23/2008 First Published: 11/4/2008


8.		Phase II Study of Docetaxel and Hydroxychloroquine in Patients With Metastatic Hormone-Refractory Chemotherapy-Naive Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				NCI				CINJ-080805 080805, 0220080244, NCT00786682

First Published: 7/10/2008


9.		Phase I Study of Hydroxychloroquine and Temozolomide in Patients With Metastatic or Unresectable Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				UPCC-12907 UPCC 12907, NCT00714181

First Published: 12/19/2008


10.		Phase I Study of Sunitinib Malate and Hydroxychloroquine in Patients With Advanced Solid Tumors Refractory to Standard Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Approved-not yet active				18 and over				NCI				CINJ-050801 050801, 0220080281, NCT00813423

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute